Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H23N5O2 |
Molecular Weight | 329.3968 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](CN3C(=O)CCC3=O)CN1CCN(C2)C4=NC=CC=N4
InChI
InChIKey=UXWBIYCPUVWKHP-KBPBESRZSA-N
InChI=1S/C17H23N5O2/c23-15-4-5-16(24)22(15)11-13-2-3-14-12-21(9-8-20(14)10-13)17-18-6-1-7-19-17/h1,6-7,13-14H,2-5,8-12H2/t13-,14-/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/9571226Curator's Comment: Description was created based on several sources, including: http://en.pharmacodia.com/web/drug/1_8718.html
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9571226
Curator's Comment: Description was created based on several sources, including: http://en.pharmacodia.com/web/drug/1_8718.html
Sunepitron (CP-93,393) is an anxiolytic drug with highly selective serotonin 5-hydroxytryptamine 1A autoreceptor agonist, alpha2-adrenergic antagonist, and dopamine D2 agonist properties. Sunepitron hydrochloride had been in Phase III clinical trials by Pfizer for the treatment of anxiety disorder and depression. However, this research has been discontinued.
CNS Activity
Originator
Sources: http://adisinsight.springer.com/drugs/800004255 | http://en.pharmacodia.com/web/drug/1_8718.html
Curator's Comment: # Pfizer
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.02 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9571226/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUNEPITRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
10.92 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9571226/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUNEPITRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.36 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9571226/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUNEPITRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
87.33 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9571226/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUNEPITRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9571226/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUNEPITRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9571226/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUNEPITRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites. | 1997 Dec |
|
Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers. | 1998 May |
|
Assay and purity evaluation of sunepitron hydrochloride by reversed-phase liquid chromatography using a reference standard composite. | 1998 Nov |
|
Psychopharmacology of depression in the next millennium. | 1999 Jul |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9571226
The excretion, biotransformation, and pharmacokinetics of Sunepitron (CP-93,393) were investigated in six healthy male volunteers after oral administration of a 5-mg dose of [14C]CP-93,393.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C47794
Created by
admin on Sat Dec 16 17:27:48 GMT 2023 , Edited by admin on Sat Dec 16 17:27:48 GMT 2023
|
||
|
NCI_THESAURUS |
C29713
Created by
admin on Sat Dec 16 17:27:48 GMT 2023 , Edited by admin on Sat Dec 16 17:27:48 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Sunepitron
Created by
admin on Sat Dec 16 17:27:48 GMT 2023 , Edited by admin on Sat Dec 16 17:27:48 GMT 2023
|
PRIMARY | |||
|
DTXSID801336204
Created by
admin on Sat Dec 16 17:27:48 GMT 2023 , Edited by admin on Sat Dec 16 17:27:48 GMT 2023
|
PRIMARY | |||
|
131831-03-3
Created by
admin on Sat Dec 16 17:27:48 GMT 2023 , Edited by admin on Sat Dec 16 17:27:48 GMT 2023
|
PRIMARY | |||
|
100000082983
Created by
admin on Sat Dec 16 17:27:48 GMT 2023 , Edited by admin on Sat Dec 16 17:27:48 GMT 2023
|
PRIMARY | |||
|
183092
Created by
admin on Sat Dec 16 17:27:48 GMT 2023 , Edited by admin on Sat Dec 16 17:27:48 GMT 2023
|
PRIMARY | |||
|
2GT50C8U60
Created by
admin on Sat Dec 16 17:27:48 GMT 2023 , Edited by admin on Sat Dec 16 17:27:48 GMT 2023
|
PRIMARY | |||
|
CHEMBL2111058
Created by
admin on Sat Dec 16 17:27:48 GMT 2023 , Edited by admin on Sat Dec 16 17:27:48 GMT 2023
|
PRIMARY | |||
|
7670
Created by
admin on Sat Dec 16 17:27:48 GMT 2023 , Edited by admin on Sat Dec 16 17:27:48 GMT 2023
|
PRIMARY | |||
|
SUB10774MIG
Created by
admin on Sat Dec 16 17:27:48 GMT 2023 , Edited by admin on Sat Dec 16 17:27:48 GMT 2023
|
PRIMARY | |||
|
C152473
Created by
admin on Sat Dec 16 17:27:48 GMT 2023 , Edited by admin on Sat Dec 16 17:27:48 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)